Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...

The damage to these cells can cause potential side effects, like fatigue, vomiting and nausea, but it’s important to note ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.